4.7 Article

Can outcomes in Duchenne muscular dystrophy be improved by public reporting of data?

Journal

NEUROLOGY
Volume 80, Issue 6, Pages 583-589

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e318282334e

Keywords

-

Funding

  1. Taro Pharmaceuticals
  2. MDA
  3. NIH
  4. US FDA
  5. Centers for Disease Control and Prevention funds [CDC-RFA-DD10-1012]

Ask authors/readers for more resources

Objective: To review current approaches for obtaining patient data in Duchenne muscular dystrophy (DMD) and consider how monitoring and comparing outcome measures across DMD clinics could facilitate standardized and improved patient care. Methods: We reviewed annual standardized data from cystic fibrosis (CF) clinics and DMD care guidelines and consensus statements; compared current approaches to obtain DMD patient data and outcome measures; and considered the best method for implementing public reporting of outcomes, to drive improvements in health care delivery. Results: Current methods to monitor DMD patient information (MD STARnet, DuchenneConnect, and TREAT-NMD) do not yet provide patients with comparative outcome data. The CF patient registry allows for reporting of standard outcomes across clinics and is associated with improved CF outcomes. A similar patient registry is under development for the Muscular Dystrophy Association (MDA) clinic network. Suggested metrics for quality care include molecular diagnosis, ambulatory status and age at loss of ambulation, age requiring ventilator support, and survival. Conclusions: CF longevity has increased by almost 33% from 1986 to 2010, in part due to a CF patient registry that has been stratified by individual care centers since 1999, and publically available since 2006. Implementation of outcome reporting for MDA clinics might promote a similar benefit to patients with DMD. Neurology (R) 2013;80:583-589

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Clinical Neurology

Long Exercise Test in Periodic Paralysis: A Bayesian Analysis

Daniel B. Simmons, Julie Lanning, James C. Cleland, Araya Puwanant, Paul T. Twydell, Robert C. Griggs, Rabi Tawil, Eric L. Logigian

MUSCLE & NERVE (2019)

Editorial Material Clinical Neurology

Editors' note: Burnout, career satisfaction, and well-being among US neurology residents and fellows in 2016

Chafic Karam, Robert C. Griggs

NEUROLOGY (2018)

Editorial Material Clinical Neurology

Editors' note: Odor identification as a biomarker of preclinical AD in older adults at risk

Chafic Karam, Robert C. Griggs

NEUROLOGY (2018)

Editorial Material Clinical Neurology

Editors' note: Activity limitations and subjective well-being after stroke

Chafic Karam, Robert C. Griggs

NEUROLOGY (2018)

Article Multidisciplinary Sciences

The tyrosine phosphorylated pro-survival form of Fas intensifies the EGF-induced signal in colorectal cancer cells through the nuclear EGFR/STAT3-mediated pathway

Ngoc Ly Ta, Krittalak Chakrabandhu, Sebastien Huault, Anne-Odile Hueber

SCIENTIFIC REPORTS (2018)

Review Pediatrics

Progress in treatment and newborn screening for Duchenne muscular dystrophy and spinal muscular atrophy

Qing Ke, Zheng-Yan Zhao, Jerry R. Mendell, Mei Baker, Veronica Wiley, Jennifer M. Kwon, Lindsay N. Alfano, Anne M. Connolly, Catherine Jay, Hanna Polari, Emma Ciafaloni, Ming Qi, Robert C. Griggs, Michele A. Gatheridge

WORLD JOURNAL OF PEDIATRICS (2019)

Review Clinical Neurology

Maximizing the Benefit of Life-Saving Treatments for Pompe Disease, Spinal Muscular Atrophy, and Duchenne Muscular Dystrophy Through Newborn Screening: Essential Steps

Mei Baker, Robert Griggs, Barry Byrne, Anne M. Connolly, Richard Finkel, Lucja Grajkowska, Amanda Haidet-Phillips, Laura Hagerty, Robert Ostrander, Lianna Orlando, Kathryn Swoboda, Michael Watson, R. Rodney Howell

JAMA NEUROLOGY (2019)

Review Oncology

TRAIL and FasL Functions in Cancer and Autoimmune Diseases: Towards an Increasing Complexity

Aurelie Rossin, Giorgia Miloro, Anne-Odile Hueber

CANCERS (2019)

Letter Clinical Neurology

Author response: Michael H. Brooke, MB, BCh (1934-2018)

Robert C. Griggs, Jerry R. Mendell

NEUROLOGY (2019)

Article Clinical Neurology

Efficacy and Safety of Dichlorphenamide for Primary Periodic Paralysis in Adolescents Compared With Adults

Emma Ciafaloni, Fredric Cohen, Robert Griggs

PEDIATRIC NEUROLOGY (2019)

Editorial Material Medicine, Research & Experimental

Cell death in the service of epithelial homeostasis

Laurent Gagnoux-Palacios, Anne-Odile Hueber

M S-MEDECINE SCIENCES (2019)

Article Biochemistry & Molecular Biology

Downregulation of thioredoxin-1-dependent CD95 S-nitrosation by Sorafenib reduces liver cancer

Raul Gonzalez, Maria A. Rodriguez-Hernandez, Maria Negrete, Kalina Ranguelova, Aurelie Rossin, Carmen Choya-Foces, Patricia de la Cruz-Ojeda, Antonio Miranda-Vizuete, Antonio Martinez-Ruiz, Sergio Rius-Perez, Juan Sastre, Jose A. Barcena, Anne-Odile Hueber, C. Alicia Padilla, Jordi Muntane

REDOX BIOLOGY (2020)

Article Biochemistry & Molecular Biology

Caspase-9 acts as a regulator of necroptotic cell death

Tamas Molnar, Petra Pallagi, Balint Tel, Robert Kiraly, Eszter Csoma, Viktoria Jenei, Zsofia Varga, Peter Gogolak, Anne Odile Hueber, Zoltan Mate, Ferenc Erdelyi, Gabor Szabo, Aladar Pettko-Szandtner, Attila Bacsi, Laszlo Virag, Jozsef Maleth, Gabor Koncz

Summary: Necroptosis is a regulated type of cell death that acts as a backup mechanism when apoptosis is inhibited or absent, and it is associated with the pathogenesis of various diseases and tumor regulation. The research found that Caspase-9 serves as a newly identified regulator of Necroptosis, offering a promising therapeutic target for manipulating the immunological outcome of cell death.

FEBS JOURNAL (2021)

Article Multidisciplinary Sciences

Chimeric virus-like particles (VLPs) designed from shrimp nodavirus (MrNV) capsid protein specifically target EGFR-positive human colorectal cancer cells

Khwanthana Grataitong, Sebastien Huault, Charoonroj Chotwiwatthanakun, Pitchanee Jariyapong, Orawan Thongsum, Chidchanok Chawiwithaya, Krittalak Chakrabandhu, Anne-Odile Hueber, Wattana Weerachatyanukul

Summary: The study successfully created three different chimeric MrNV virus-like particles with specificity towards the epidermal growth factor receptor (EGFR) for targeted cancer drug delivery. These chimeric particles demonstrated enhanced binding and internalization abilities specific to EGFR-positive cells, showcasing their potential as nanocontainers for targeted cancer drug delivery.

SCIENTIFIC REPORTS (2021)

Review Clinical Neurology

N-of-1 Trials in Neurology A Systematic Review

Bas C. Stunnenberg, Joost Berends, Robert C. Griggs, Jeffrey Statland, Gea Drost, Jane Nikles, Hans Groenewoud, Baziel G. M. van Engelen, Wilt Jan van der Gert, Joost Raaphorst

Summary: This study conducted a systematic review of published N-of-1 trials in neurologic disorders, focusing on methodological quality and reporting. Most trials were in neuromuscular and neurodegenerative/movement disorders, with applications in stable chronic conditions and progressive or acute disorders. N-of-1 trials show potential for bridging the gap between research and clinical care by providing a personalized evidence base for suitable treatments.

NEUROLOGY (2022)

No Data Available